Serine/threonine kinase 11 (STK11), also known as liver kinase B1 (LKB1), is a major tumor suppressor gene in lung cancer . Many studies have demonstrated that STK11 is the most inactivated tumor suppressor gene in NSCLC [2–4]. A previous study has showed that among 107 lung adenocarcinomas analyzed, 29 (27.1%) harbored LKB1 genetic alteration .
Prognostic significance concerning STK11 status in NSCLC has been mostly sounded out in surgically resected tumors, where evidence concerning its role is not yet exhaustive . In addition, enough attention has been paid to the immunotherapy of lung adenocarcinoma patients harbored STK11 mutation. Biton J et al. revealed TP53 mutation without co-occurring STK11 or EGFR alterations, independently of KRAS mutation, identified the group of tumors with the highest CD8 Tcell density and PD-L1 expression . Another study by Skoulidis F identified STK11 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma . It is necessary to study the relationship between STK11 mutation and immune related prognosis markers and immune microenvironment. However, there are relatively few studies to focus on this issue.
In our present study, using the cBioPortal and TIMER database [9,10], we mainly analyze the STK11 mutation status, the relationship between STK11 mutation and immune related prognostic markers and immune microenvironment. In addition, we compare the survival difference for patients harbored STK11 mutation and none.
本文分享自微信公众号 - 芒果先生聊生信（from2019to2020）。
如有侵权，请联系 email@example.com 删除。